Navigation Links
International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia

NEW YORK, December 16 /PRNewswire/ -- International, well-known scientific experts were surprised by the publication of GFT505 (80 mg/day) data presented as "extremely promising."[1] More than 50 internationally recognized expert scientists and clinicians critically reviewed these data. These experts reaffirmed the continuing role of generic lipid-modifying treatments, fenofibrate and bezafibrate, in treating atherogenic dyslipidemia, which is commonly observed in patients with metabolic syndrome and type 2 diabetes and is characterized by elevated triglycerides and low 'good' high-density lipoprotein (HDL) cholesterol. Published clinical data also already indicate a potential role for fenofibrate in treating non-alcoholic fatty liver disease.[1]

    Reviewing published evidence, these experts argued that:

    - Elevated triglycerides (>150 mg/dL) are decreased by 43% with
      generic fenofibrate[2] and 32% with generic bezafibrate[2]
    - Low HDL cholesterol (<40 mg/dL) is increased by 18%[3],[4]

Either agent is approximately two-fold more effective than 80 mg of GFT505, an investigational agent currently in early phase II development.[5]

                      GFT505     Fenofibrate        Bezafibrate

    Triglycerides      -21%     -43 percent[6]     -32 percent[7]

    HDL-C (<40mg/dL)    +9%    +18,8 percent[8]   +17,9 percent[9]

Published data show a potential role for fenofibrate in treating non-alcoholic fatty liver disease, significantly decreasing the proportion of patients with liver dysfunction.[1]

Fenofibrate significantly reduced both liver enzymes, alanine amino transferase (ALT) and aspartate amino transferase (AST), unlike GFT505.[10]

Commenting on these data, these experts said: 'These new data show that GFT505 is unlikely to have the potential to replace generic fenofibrate and bezafibrate in treating patients with atherogenic dyslipidemia.'


    [1] Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G,
        Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the
        treatment of non-alcoholic fatty liver disease. Dig Liver Dis
    [2] Ruotolo G, Ericsson CG, Tettamanti C, Karpe F, Grip L, Svane B,
        Nilsson J, de Faire U, Hamsten A. Treatment effects on serum
        lipoprotein lipids, apolipoproteins and low density lipoprotein
        particle size and relationships of lipoprotein variables to
        progression of coronary artery disease in the Bezafibrate Coronary
        Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol
    [3] Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ,
        Mitchel YB, Gumbiner B; Ezetimibe Study Group. Efficacy and safety
        of the coadministration of ezetimibe with fenofibrate in patients
        with mixed hyperlipidaemia Eur Heart J 2005;26:897.
    [4] The BIP Study Group. Secondary prevention by raising HDL cholesterol
        and reducing triglycerides in patients with coronary artery disease:
        the Bezafibrate Infarction Prevention (BIP) study. Circulation
    [5] Press release. GENFIT: Extremely promising GFT505 results in
        Phase II.
        PR_GENFIT_GFT505_Results.pdf. [Accessed 4 Dec 2009].
    [6] Farnier et al, Eu Heart J. 2005,26:897
    [7] Ruotulo et al, JACC Vol 32, b 6 November 15 1998:1648-56
    [8] Farnier et al, Eu Heart J, 2005, 26:897
    [9] The BIO Study Group, Circulation, Volume 102(1)4 July 2000pp 21-27
    [10] Press release. GENFIT: A new potential indication for GFT505,
         diabetes associated fatty liver disease.

(Due to the length of the above URLs, it may be necessary to copy and paste those hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

SOURCE international experts

SOURCE international experts
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
2. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
3. Chindex International, Inc. to Report Second Quarter Fiscal 2010 Financial Results
4. Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results
5. Natural Alternatives International, Inc. Announces Filing of Patent Infringement Lawsuit
6. New Database from ANSI, AAMI, ASTM International, and DIN Provides Centralized Source of Information for Medical Device Professionals
7. DAVISCO Foods International, Inc. and MEGGLE Group Announce a Joint Venture for the Production of Pharmaceutical Lactose.
8. Lexington International, LLC Receives 2009 U.S. Presidents E Award Recognizing its Export Achievements
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
11. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Figure 1, a free mobile-first ... medical cases, has launched a new completely redesigned web ... version allows radiologists, who work primarily on a desktop, ... engage with its radiologist user base, Figure 1 is ... North America (RSNA) Annual Meeting. ...
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... -- The uptake of recently approved and pipeline premium products ... market growth to 2021, says GBI Research . ... for Type 1 Diabetes Mellitus (T1DM), will be a key driver of ... --> The uptake of recently approved and pipeline premium ... of market growth to 2021, says GBI Research ...
Breaking Medicine Technology:
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the Business Action on Health Awards, bestowed annually to the world’s best corporate-supported ... commended companies at Global Health Council’s Landscape Symposium held in Washington D.C and ...
(Date:11/24/2015)... ... 2015 , ... The OSHA Training Center at Chabot-Las ... in Northern California, is calling on retail employers to implement safety measures to ... volume of sales and shoppers rapidly expands, retailers are strongly encouraged to develop ...
(Date:11/24/2015)... ... , ... There’s nothing better than giving the gift of green this holiday ... , This year, gardens are popping up in the most unexpected places. A variety ... Gardens’ African Keyhole Garden Bed ($499) , Water conscious gardeners – and that should ...
(Date:11/24/2015)... ... November 24, 2015 , ... Wireless Analytics, an ... announced new 24-hour weekday support capability. The “all hours” offering was introduced ... international customers, and to enhance after-hours support available in the US. , Available ...
(Date:11/24/2015)... ... , ... Take the audience on a journey with TransFrame Cloud from Pixel Film ... images without ever setting a single keyframe in Final Cut Pro X. Design smooth and ... to change the angle and depth of field to create a unique viewing perspective. , ...
Breaking Medicine News(10 mins):